General Session 3
Zusammenfassungen erscheinen bald
- GS03-01 Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of E4112
- GS03-02 Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography
- GS03-03 Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial
- GS03-04 Novel Mechanisms of CDH1 Inactivation in Breast Invasive Lobular Carcinoma Unveiled by the Integration of Artificial Intelligence and Genomics
- GS03-06 Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial
- GS03-07 Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer
- GS03-09 Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers
- GS03-10 Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations
- GS03-11 Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity
Seema Khan, Justin Romanoff, Constantine Gatsonis, et al.
GS03-01 Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of E4112
Zusammenfassung folgt
Janet Dunn, Peter Donnelly, Nada Elbeltagi, et al.
GS03-02 Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography
Zusammenfassung folgt
Gabriel Hortobagyi, Daniil Stroyakovsky, Denise Yardley, et al.
GS03-03 Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial
Zusammenfassung folgt
Fresia Pareja, Higinio Dopeso, Yikan Wang, et al.
GS03-04 Novel Mechanisms of CDH1 Inactivation in Breast Invasive Lobular Carcinoma Unveiled by the Integration of Artificial Intelligence and Genomics
Zusammenfassung folgt
Nicholas Turner, Jorge Reis-Filho, Matthew Goetz, et al.
GS03-06 Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial
Zusammenfassung folgt
Daniel Stover, Dominik Hlauschek, Erica Mayer, et al.
GS03-07 Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer
Zusammenfassung folgt
Nolan Priedigkeit, Alinés Lebrón-Torres, Janny Liao, et al.
GS03-09 Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers
Zusammenfassung folgt
Andreas Varkaris, Ferran Fece de la Cruz, Elizabeth Martin , et al.
GS03-10 Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations
Zusammenfassung folgt
Kathleen Houlahan, Aziz Khan, Noah Greenwald, Janny Liao, et al.
GS03-11 Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity
Zusammenfassung folgt